| Value | ₹23.92 Cr |
|---|
NSE filing, NSE: RCDL. Summary written from the filing by ALFA Finder's alert engine.
Rajgor Castor Derivatives Ltd: key numbers
- Share price
- ₹16.30
- Market cap
- ₹77.96 Cr
- Revenue (annual)
- ₹872.2 Cr
- Net profit (annual)
- ₹12.63 Cr
- P/E (TTM)
- 6.2×Sector 38.6×
- Promoter holding
- 55.18%
- FII holding
- 2.29%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rajgor Castor Derivatives Ltd
All →Rajgor Castor Derivatives Other Announcement
Rajgor Castor Derivatives files its integrated governance report for the half year ended September 30, 2026. The routine compliance filing contains no transaction or financial figures.
Rajgor Castor Derivatives Capital Structure Change
Rajgor Castor Derivatives Limited has allotted 23,913,000 equity shares pursuant to its rights issue. The company's paid-up share capital has increased following this allotment.
Rajgor Castor Derivatives Capital Structure Change
Rajgor Castor Derivatives Limited allotted 2.39 crore equity shares on a rights basis at Rs. 10 per share, raising approximately Rs. 23.91 crore.
- Value
- ₹23.91 Cr
Rajgor Castor Derivatives Capacity Expansion: ₹61.5 Cr Investment
Rajgor Castor Derivatives Ltd is expanding manufacturing capacity by 348 MT/day with a ₹61.50 Crore investment, funded by term loans and internal accruals.
- Value
- ₹61.50 Cr
- Execution
- Approx 10 months
- manufacturing capacity
- 348.0 MT per day
Rajgor Castor Derivatives Price Movement Clarification
Rajgor Castor Derivatives Limited clarified to the NSE that the recent movement in its share price is market-driven and not due to undisclosed material information.
Rajgor Castor Derivatives Annual General Meeting
RCDL filed proceedings of its 8th AGM held September 18, 2026, adopting FY26 financials and approving a ₹0.10 per share dividend among other resolutions.
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr